Panacea Biotec Limited (NSE:PANACEABIO)
India
· Delayed Price · Currency is INR | Market Cap | 26.73B |
| Revenue (ttm) | 5.63B |
| Net Income (ttm) | -79.13M |
| Shares Out | 61.25M |
| EPS (ttm) | -1.36 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 194,598 |
| Average Volume | 426,005 |
| Open | 435.20 |
| Previous Close | 443.80 |
| Day's Range | 421.65 - 440.90 |
| 52-Week Range | 112.35 - 490.55 |
| Beta | 0.92 |
| RSI | 56.55 |
| Earnings Date | May 26, 2025 |
About Panacea Biotec
Panacea Biotec Limited, a biotechnology company, engages in the research, development, manufacture, and marketing of vaccines, pharmaceutical formulations, nutraceuticals, and food and nutrition products in India and internationally. It operates through Vaccines and Formulations segments. The company’s product portfolio includes prescription products in various therapeutic areas, such as transplantation, renal disease, oncology, respiratory, pain management, diabetes and cardiovascular management, gastro-intestinal care, nephrology, osteoporosi... [Read more]
Financial Performance
In 2023, Panacea Biotec's revenue was 5.59 billion, an increase of 21.57% compared to the previous year's 4.60 billion. Losses were -11.73 million, -96.47% less than in 2022.
Financial StatementsNews
Panacea Biotec subsidiary launches baby care products under “NikoMom” brand
Panacea Biotec Pharma Limited (PBPL), a wholly owned subsidiary of Panacea Biotec, has entered the baby care market with the launch of premium baby diapers and wipes under the brand name “NikoMom.” Ke...
Panacea Biotec shares hit 5% upper circuit after securing Rs 127 crore vaccine supply contract from UNICEF
Panacea Biotec Ltd has surged to its 5% upper circuit, trading at ₹454.90, following the announcement of a significant Letter of Award from UNICEF. The company has been entrusted with the supply of 11...
Panacea Biotec secures Rs 127 crore UNICEF order for bivalent oral polio vaccine
Panacea Biotec Ltd has received a significant Letter of Award from UNICEF to supply 115 million doses of its bivalent oral polio vaccine (bOPV) for the calendar year 2025. The total contract value is ...
Panacea Biotec aims to launch dengue vaccine in next 2-3 years
Panacea Biotec is gearing up to launch its dengue vaccine in the next 2-3 years, according to the company’s Chairman and Managing Director, Dr. Rajesh Jain. The vaccine, developed in collaboration wit...
Panacea Biotec secures $20 million loan from DFC for vaccine capacity expansion
Panacea Biotec, a leading biotechnology company in India, has received a long-term loan commitment of up to $20 million from the U.S. International Development Finance Corporation (DFC). The funding w...
Panacea Biotec shares surge over 3% in intraday trading
Panacea Biotec’s share witnessed a significant surge on the National Stock Exchange (NSE) today, rising more than 3%. The stock stock opened at ₹225.95. The stock hit a day high of ₹239.00 and a low o...
Phase-3 clinical trial of dengue vaccine starts
The phase 3 clinical trial of India's first dengue vaccine, DengiAll, began in Rohtak, Haryana. Developed by Panacea Biotec and supported by ICMR, the trial involves 10,335 participants across 19 site...
Phase three clinical trial of India's own dengue vaccine, DengiAll, initiated
India's first phase-three trial for an indigenous tetravalent dengue vaccine, DengiALL, was initiated by Panacea Biotec. Conducted across 19 sites, the trial involves over 10,335 healthy adults. The v...